https://www.modernretina.com/view/getting-to-the-root-of-geographic-atrophy-diagnosis-and-management2026-04-03T10:01:00Z2026-04-03T10:01:00Z https://www.modernretina.com/view/first-patient-dosed-in-phase-i-ii-trial-of-complement-targeting-gene-therapy-for-geographic-atrophy2026-04-02T12:53:00Z2026-04-02T12:53:00Z https://www.modernretina.com/view/taking-a-step-beyond-low-vision-aids-to-sharpen-the-focus-on-visual-rehabilitation2026-04-01T15:08:00Z2026-04-01T15:08:00Z https://www.modernretina.com/view/aflibercept-to-treat-rop-in-extremely-low-birth-weight-children2026-03-30T10:00:00Z2026-03-30T10:00:00Z https://www.modernretina.com/view/multi-luminance-shape-discrimination-test-shows-reliability-in-low-vision-rp-population2026-03-27T12:00:00Z2026-03-27T12:00:00Z https://www.modernretina.com/view/phase-2-topline-data-ocugen-ocu410-reduces-geographic-atrophy-lesion-growth-by-31-at-12-months2026-03-24T16:15:05.953Z2026-03-24T16:15:05.953Z https://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-moving-beyond-anti-vegf-with-otx-tki-and-pravin-u-dugel-md2026-03-23T04:00:00Z2026-03-23T04:00:00Z https://www.modernretina.com/view/onl-therapeutics-randomizes-first-european-patient-in-phase-2-ga-trial-of-xelafaslatide2026-03-16T14:45:46.896Z2026-03-16T14:45:46.896Z https://www.modernretina.com/view/genetic-retinoblastoma-risk-stratified-by-age-among-patients-with-metachronous-bilateral-conversion2026-03-13T19:00:00Z2026-03-13T19:00:00Z https://www.modernretina.com/view/galimedix-therapeutics-earns-milestone-payment-in-ophthalmology-partnership-with-th-a-open-innovation2026-03-13T14:15:01.231Z2026-03-13T14:15:01.231Z https://www.modernretina.com/view/ophthalmic-drug-shortages-more-frequent-longer-lasting-than-average2026-03-13T14:15:00.015Z2026-03-13T14:15:00.015Z https://www.modernretina.com/view/johnson-johnson-s-tecnis-puresee-edof-iol-cleared-for-us-market2026-03-12T14:15:00Z2026-03-12T14:15:00Z https://www.modernretina.com/view/eichenbaum-acorns-collaborative-retina-care-with-jeffrey-gerson-od2026-03-11T12:00:00Z2026-03-11T12:00:00Z https://www.modernretina.com/view/novabridge-visara-report-positive-phase-2a-results-for-dual-vegf-a-ang-2-inhibitor-vis-1012026-03-11T10:55:00Z2026-03-11T10:55:00Z https://www.modernretina.com/view/fda-clears-phase-i-ii-trial-of-svt-001-cell-therapy-for-familial-drusen-associated-vision-loss2026-03-10T15:53:10.135Z2026-03-10T15:53:10.135Z https://www.modernretina.com/view/ocugen-completes-enrollment-in-limelight-phase-3-trial-of-ocu400-for-retinitis-pigmentosa2026-03-10T15:50:27.085Z2026-03-10T15:50:27.085Z https://www.modernretina.com/view/pegcetacoplan-does-not-impact-anti-vegf-treatment-in-geographic-atrophy-with-ted-leng-md-ms2026-03-03T19:30:00Z2026-03-03T19:30:00Z https://www.modernretina.com/view/eylea-8mg-in-rvo-quasar-clinical-perspectives-video2026-03-03T16:00:16.631Z2026-03-03T16:00:16.631Z https://www.modernretina.com/view/eylea-8mg-in-rvo-snapshot-of-the-64-week-quasar-data2026-03-03T15:01:35.529Z2026-03-03T15:01:35.529Z https://www.modernretina.com/view/q-a-ai-predicted-retinal-function-shows-promise-in-geographic-atrophy2026-02-24T13:38:15.558Z2026-02-24T13:38:15.558Z https://www.modernretina.com/view/dr-mali-s-top-5-predictions-in-ophthalmology-for-20262026-02-24T13:00:35.570Z2026-02-24T13:00:35.570Z https://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-tracking-retinal-gene-therapies-with-arshad-m-khanani-md-ma-fasrs2026-02-23T21:00:00Z2026-02-23T21:00:00Z https://www.modernretina.com/view/gennady-landa-md-shares-clinical-insights-on-the-ranibizumab-ocular-implant2026-02-20T18:00:00Z2026-02-20T18:00:00Z https://www.modernretina.com/view/samsung-bioepis-reaches-settlement-agreement-for-eylea-aflibercept-biosimilar2026-02-17T18:00:00Z2026-02-17T18:00:00Z https://www.modernretina.com/view/iss-2026-highlights-advances-in-ophthalmic-imaging-for-retinal-practice2026-02-14T16:00:00Z2026-02-14T16:00:00Z https://www.modernretina.com/view/american-college-of-physicians-policy-paper-urges-medical-community-to-drop-the-term-provider-2026-02-10T15:50:00Z2026-02-10T15:50:00Z https://www.modernretina.com/view/prima-system-a-major-step-in-the-battle-against-ga2026-02-10T11:00:00Z2026-02-10T11:00:00Z https://www.modernretina.com/view/meiragtx-licenses-complement-targeted-geographic-atrophy-program-from-zipbio2026-02-09T15:22:53.227Z2026-02-09T15:22:53.227Z https://www.modernretina.com/view/metformin-use-associated-with-reduced-incidence-of-intermediate-amd2026-02-09T15:19:21.799Z2026-02-09T15:19:21.799Z https://www.modernretina.com/view/fda-decision-carbachol-brimonidine-ophthalmic-solution-approved-for-presbyopia-following-brio-phase-3-results2026-01-29T13:00:20.093Z2026-01-29T13:00:20.093Z https://www.modernretina.com/view/new-optoretinography-technique-allows-direct-measurement-of-rod-function-in-vivo2026-01-26T11:00:00Z2026-01-26T11:00:00Z https://www.modernretina.com/view/navigating-geographic-atrophy-from-biomarkers-to-bilateral-therapy2026-01-23T19:09:00Z2026-01-23T19:09:00Z https://www.modernretina.com/view/ollin-biosciences-reports-positive-head-to-head-phase-1b-data-for-oln324-vs-faricimab2026-01-23T16:51:00Z2026-01-23T16:51:00Z https://www.modernretina.com/view/eichenbaum-acorns-mentorship-momentum-and-the-making-of-a-retina-podcast2026-01-23T05:00:00Z2026-01-23T05:00:00Z https://www.modernretina.com/view/long-lived-greenland-sharks-may-point-to-new-approaches-for-retinal-disease2026-01-21T11:00:00Z2026-01-21T11:00:00Z https://www.modernretina.com/view/molecular-insights-and-clinical-experience-extending-anti-vegf-durability2026-01-19T11:00:00Z2026-01-19T11:00:00Z https://www.modernretina.com/view/q-a-evolving-approaches-to-geographic-atrophy-management2026-01-15T14:20:11.419Z2026-01-15T14:20:11.419Z https://www.modernretina.com/view/nanoscope-secures-new-us-patent-for-multi-characteristic-opsin-mco-technology-platform2026-01-15T11:00:00Z2026-01-15T11:00:00Z https://www.modernretina.com/view/rates-of-retinal-layer-thinning-predict-visual-field-progression-in-glaucoma2026-01-14T11:00:00Z2026-01-14T11:00:00Z https://www.modernretina.com/view/exploring-emerging-therapies-in-the-retinal-vascular-disease-pipeline2026-01-13T13:00:00Z2026-01-13T13:00:00Z https://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-targeting-the-fas-signaling-pathway-with-david-zacks-md-phd2026-01-13T11:30:00Z2026-01-13T11:30:00Z https://www.modernretina.com/view/first-patient-treated-in-dose-expansion-portion-of-splicebio-s-phase-1-2-astra-clinical-trial2026-01-13T11:00:00Z2026-01-13T11:00:00Z https://www.modernretina.com/view/fda-grants-fast-track-designation-to-complement-therapeutics-ctx001-for-geographic-atrophy2026-01-12T15:33:29.811Z2026-01-12T15:33:29.811Z https://www.modernretina.com/view/8-things-to-know-about-aflibercept-8-mg-for-retinal-vascular-disease2026-01-12T11:00:00Z2026-01-12T11:00:00Z https://www.modernretina.com/view/a-new-treatment-round-up-for-amd-and-ga2026-01-09T19:13:00Z2026-01-09T19:13:00Z https://www.modernretina.com/view/floretina-inadvertent-anti-vegf-interval-increases-during-the-covid-19-pandemic2026-01-09T11:00:00Z2026-01-09T11:00:00Z https://www.modernretina.com/view/primavera-study-central-vision-improvement-with-subretinal-implant2026-01-08T11:00:00Z2026-01-08T11:00:00Z https://www.modernretina.com/view/staar-surgical-terminates-proposed-acquisition-by-alcon2026-01-07T15:09:27.304Z2026-01-07T15:09:27.304Z https://www.modernretina.com/view/macular-laser-picks-up-speed-the-technology-accelerating-retinal-therapies2026-01-07T11:00:00Z2026-01-07T11:00:00Z https://www.modernretina.com/view/evaluating-safety-and-clinical-confidence-between-aflibercept-8-mg-and-2-mg-in-retinal-vascular-diseases2026-01-06T13:05:00Z2026-01-06T13:05:00Z https://www.modernretina.com/view/management-approaches-for-suboptimal-responders-in-amd-dme-and-rvo2026-01-06T13:00:00Z2026-01-06T13:00:00Z https://www.modernretina.com/view/treating-mactel-first-identify-patient-candidates-and-appropriate-eye-selection2026-01-05T11:00:00Z2026-01-05T11:00:00Z https://www.modernretina.com/view/inside-the-mindset-of-an-early-adopter2026-01-02T11:00:00Z2026-01-02T11:00:00Z https://www.modernretina.com/view/fda-outlook-therapeutics-complete-response-letter-ons-50102025-12-31T22:45:32.430Z2025-12-31T22:45:32.430Z https://www.modernretina.com/view/challenges-for-young-physicians-treating-patients-with-ga2025-12-31T11:00:00Z2025-12-31T11:00:00Z https://www.modernretina.com/view/comparing-aflibercept-8-mg-and-faricimab-in-rvo2025-12-30T13:05:00Z2025-12-30T13:05:00Z https://www.modernretina.com/view/insights-from-privotal-trials-for-aflibercept-8-mg-in-rvo2025-12-30T13:00:00Z2025-12-30T13:00:00Z https://www.modernretina.com/view/a-medical-fellow-finds-some-magic-at-the-aao-annual-meeting2025-12-26T11:00:00Z2025-12-26T11:00:00Z https://www.modernretina.com/view/aao-highlight-looking-ahead-to-20262025-12-24T11:00:00Z2025-12-24T11:00:00Z https://www.modernretina.com/view/how-ai-is-reshaping-ophthalmology-in-2025-and-beyond2025-12-23T14:14:51.523Z2025-12-23T14:14:51.523Z https://www.modernretina.com/view/evaluating-retinal-drying-durability-and-iop-management-with-second-generation-anti-vegf-therapies-in-retinal-vascular-diseases2025-12-23T13:05:00Z2025-12-23T13:05:00Z https://www.modernretina.com/view/loading-dose-adjustments-and-treatment-switching-strategies-in-retinal-vascular-diseases2025-12-23T13:00:00Z2025-12-23T13:00:00Z https://www.modernretina.com/view/seeing-the-difference-multimodal-imaging-for-amd-and-ga2025-12-22T11:00:00Z2025-12-22T11:00:00Z https://www.modernretina.com/view/floretina-2025-eu-rop-registry-bridges-borders-for-real-world-insight2025-12-19T11:00:00Z2025-12-19T11:00:00Z https://www.modernretina.com/view/the-atrophy-advisor-an-online-tool-to-inform-ga-treatment-decisions2025-12-18T17:00:00.544Z2025-12-18T17:00:00.544Z https://www.modernretina.com/view/floretina-2025-updates-on-tinlarebant-in-adolescent-stargardt-disease2025-12-18T11:00:00Z2025-12-18T11:00:00Z https://www.modernretina.com/view/floretina-2025-long-term-follow-up-in-pediatric-gene-therapy2025-12-17T11:00:00Z2025-12-17T11:00:00Z https://www.modernretina.com/view/enhancing-durability-and-fluid-control-with-aflibercept-8-mg-in-retinal-vascular-diseases2025-12-16T13:05:00Z2025-12-16T13:05:00Z https://www.modernretina.com/view/evolving-therapeutic-strategies-with-next-generation-anti-vegf-agents-in-retinal-vascular-diseases2025-12-16T13:00:00Z2025-12-16T13:00:00Z https://www.modernretina.com/view/timely-interventions-can-protect-vision-in-patients-with-ga2025-12-16T11:00:00Z2025-12-16T11:00:00Z https://www.modernretina.com/view/aviceda-therapeutics-reports-positive-phase-2b-siglec-results-for-avd-104-in-geographic-atrophy2025-12-15T21:00:20.596Z2025-12-15T21:00:20.596Z https://www.modernretina.com/view/monitoring-mactel-why-bcva-does-not-tell-the-whole-story2025-12-15T11:00:00Z2025-12-15T11:00:00Z https://www.modernretina.com/view/ocular-therapeutix-accelerates-nda-submission-plans-for-axpaxli-for-wet-amd2025-12-12T11:00:00Z2025-12-12T11:00:00Z https://www.modernretina.com/view/onl-therapeutics-reports-positive-phase-1b-data-for-xelafaslatide-in-geographic-atrophy2025-12-10T19:00:06.216Z2025-12-10T19:00:06.216Z https://www.modernretina.com/view/how-european-clinicians-are-revolutionizing-retina-care2025-12-10T11:00:00Z2025-12-10T11:00:00Z https://www.modernretina.com/view/research-supports-iron-dysregulation-may-drive-amd2025-12-10T11:00:00Z2025-12-10T11:00:00Z https://www.modernretina.com/view/clinical-insights-shaping-real-world-decision-making-in-geographic-atrophy2025-12-09T16:54:16.869Z2025-12-09T16:54:16.869Z https://www.modernretina.com/view/managing-geographic-atrophy-in-a-90-year-old-patient-with-coexisting-neovascular-amd-and-recurrent-cnv-activation2025-12-09T16:47:22.440Z2025-12-09T16:47:22.440Z https://www.modernretina.com/view/evaluating-progressive-multifocal-geographic-atrophy-in-an-asymptomatic-81-year-old-male2025-12-09T16:43:02.387Z2025-12-09T16:43:02.387Z https://www.modernretina.com/view/managing-fovea-threatening-bilateral-geographic-atrophy-in-a-highly-independent-90-year-old-patient2025-12-09T16:38:39.538Z2025-12-09T16:38:39.538Z https://www.modernretina.com/view/advancing-geographic-atrophy-care-early-detection-imaging-innovations-and-evolving-treatment-strategies2025-12-09T16:00:46.686Z2025-12-09T16:00:46.686Z https://www.modernretina.com/view/dual-pathway-inhibition-with-faricimab-differentiating-mechanisms-in-retinal-vascular-diseases2025-12-09T13:05:00Z2025-12-09T13:05:00Z https://www.modernretina.com/view/understanding-aflibercept-s-structural-design-and-use-of-high-dose-in-retinal-vascular-diseases2025-12-09T13:00:00Z2025-12-09T13:00:00Z https://www.modernretina.com/view/inflammasome-therapeutics-completes-phase-2-trial-enrollment-for-k8-in-ga2025-12-09T11:00:00Z2025-12-09T11:00:00Z https://www.modernretina.com/view/the-gene-therapy-shift-a-closer-look-at-the-science-powering-next-generation-retinal-treatments2025-12-08T19:00:00Z2025-12-08T19:00:00Z https://www.modernretina.com/view/qa-veeral-sheth-personalized-imaging-geographic-atrophy2025-12-08T11:00:00Z2025-12-08T11:00:00Z https://www.modernretina.com/view/understanding-fluid-fluctuation-in-retinal-disorders2025-12-07T23:30:00Z2025-12-07T23:30:00Z https://www.modernretina.com/view/floretina-2025-mary-elizabeth-hartnett-rop-research-risk-management2025-12-07T19:00:00Z2025-12-07T19:00:00Z https://www.modernretina.com/view/from-ai-to-injury-patterns-insights-from-emerging-ophthalmic-research2025-12-06T19:00:00Z2025-12-06T19:00:00Z https://www.modernretina.com/view/floretina-2025-reframing-retinal-disease-choroidal-health2025-12-06T19:00:00Z2025-12-06T19:00:00Z https://www.modernretina.com/view/floretina-2025-antithrombotic-use-examined-in-wet-amd-submacular-hemorrhage2025-12-06T15:45:00Z2025-12-06T15:45:00Z https://www.modernretina.com/view/floretina-2025-navigating-antithrombotic-therapy-in-wet-amd2025-12-05T19:30:00Z2025-12-05T19:30:00Z https://www.modernretina.com/view/floretina-2025-remotely-managing-patients-with-neovascular-age-related-macular-degeneration2025-12-05T18:05:00Z2025-12-05T18:05:00Z https://www.modernretina.com/view/floretina-2025-rajvardhan-azad-on-bridging-global-gaps-in-rop-care2025-12-05T15:35:00Z2025-12-05T15:35:00Z https://www.modernretina.com/view/floretina-2025-using-multimodal-imaging-to-rethink-terson-syndrome2025-12-05T13:00:00Z2025-12-05T13:00:00Z https://www.modernretina.com/view/floretina-2025-multimodal-deep-learning-for-ckd-diagnosis-using-retinal-images-and-urine-dipstick-data2025-12-05T13:00:00Z2025-12-05T13:00:00Z https://www.modernretina.com/view/floretina-2025-weight-and-pma-play-central-roles-in-preterm-foveal-development2025-12-04T19:30:00Z2025-12-04T19:30:00Z https://www.modernretina.com/view/floretina-2025-port-delivery-system-shows-reliable-6-month-durability-and-sustained-efficacy-in-neovascular-amd-for-up-to-7-years2025-12-04T17:40:00Z2025-12-04T17:40:00Z https://www.modernretina.com/view/floretina-2025-fibrosis-a-limiting-factor-in-visual-acuity-outcomes-in-neovascular-amd2025-12-04T17:30:00Z2025-12-04T17:30:00Z https://www.modernretina.com/view/floretina-2025-ai-at-the-forefront-of-rop-care2025-12-04T13:00:00Z2025-12-04T13:00:00Z